It's the second year in a row that Lilly has used the Oscars as a platform to drive home a message about GLP-1-based obesity ...

California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate. In this ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on ValueInvestorsClub by cable888. In this article, we will ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...